论文部分内容阅读
目的:探讨前列地尔治疗新生儿持续性肺动脉高压(PPHN)的疗效。方法:采用回顾性研究方法,选取我院2008年1月至2014年8月收治的PPHN患儿115例,其中2008-2010年入院的未应用前列地尔治疗的48例作为对照组,2011年1月至2014年8月入院的应用前列地尔治疗的67例作为观察组,比较两组患儿治疗前后血氧分压(Pa O2)、平均动脉压(MAP)、肺动脉收缩压(SPAP)、氧合指数(OI)等变化,观察前列地尔的疗效。结果:观察组总有效率为77.6%,高于对照组的60.4%(P<0.05)。两组患儿治疗前各指标水平比较差异均无统计学意义(P均>0.05),治疗后(24 h、48 h)Pa O2、OI均升高,SPAP下降,且观察组改善程度大于对照组(P<0.05)。结论:应用前列地尔治疗PPHN,能提高Pa O2、OI水平,降低肺动脉压力,疗效肯定。
Objective: To investigate the efficacy of alprostadil in the treatment of neonatal persistent pulmonary hypertension (PPHN). Methods: A retrospective study was conducted to select 115 children with PPHN admitted from January 2008 to August 2014 in our hospital. Among them, 48 patients who did not use alprostadil treated in 2008-2010 were selected as control group. From January to August 2014, 67 patients treated with alprostadil were selected as observation group. PaO2, MAP and SPAP were compared between two groups before and after treatment. , Oxygenation index (OI) and other changes observed Alprostadil efficacy. Results: The total effective rate in observation group was 77.6%, which was higher than that in control group (60.4%, P <0.05). There was no significant difference between the two groups before treatment (P> 0.05). PaO2 and OI increased and SPAP decreased after 24 h and 48 h treatment, and the improvement in observation group was more than that in control group Group (P <0.05). Conclusion: The application of alprostadil for the treatment of PPHN can increase the levels of Pa O2 and OI and decrease the pulmonary artery pressure, and the curative effect is definite.